1.

Record Nr.	UNINA990001717590403321
Autore	Società italiana di biogeografia
Titolo	Lavori della Società italiana di biogeografia : X congresso nazionale, Sassari, 27-31 maggio 1964 / Società Italiana di Biogeografia
Pubbl/distr/stampa	Sassari : Istituto di entomologia agraria dell'Università di Sassari, 1964
Descrizione fisica	226 p. ; 24 cm
Disciplina	574.9
Locazione	FAGBC
Collocazione	60 551 B 85
Lingua di pubblicazione	Italiano
Formato	Materiale a stampa
Livello bibliografico	Monografia

2.

Record Nr.	UNISALENTO991002211129707536
Autore	Conso, Giovanni
Titolo	Profili del nuovo codice di procedura penale : Appendice di aggiornamento con la legge 8 agosto 1995, n. 332 : Modifiche al codice di procedura penale in tema di semplificazione dei procedimenti, di misure cautelari e di diritto di difesa / Giovanni Conso, Vittorio Grevi
Pubbl/distr/stampa	Padova : CEDAM, 1995
ISBN	8813195567
Edizione	[3. ed.]
Descrizione fisica	77 p. ; 24 cm.
Altri autori (Persone)	Grevi, Vittorioauthor
Disciplina	345.4505
Lingua di pubblicazione	Italiano
Formato	Materiale a stampa
Livello bibliografico	Monografia

3.	Record Nr.	UNINA9910503001003321
	Titolo	Nuclear receptors : the art and science of modulator design and discovery / / Mostafa Z. Badr, editor
	Pubbl/distr/stampa	Cham, Switzerland : , : Springer, , [2021] ©2021
	ISBN	3-030-78315-4
	Descrizione fisica	1 online resource (676 pages)
	Disciplina	572.8845
	Soggetti	Nuclear receptors (Biochemistry) Receptors nuclears (Bioquímica) Llibres electrònics
	Lingua di pubblicazione	Inglese
	Formato	Materiale a stampa
	Livello bibliografico	Monografia
	Nota di contenuto	Intro -- Preface -- Contents -- About the Editor -- Chapter 1: Molecular Pharmacology of the Youngest Member of the Nuclear Receptor Family: The Mineralocorticoid Receptor -- 1.1 An Overview of the MR Physiology -- 1.2 Evolutionary Profile of the MR -- 1.3 The Hsp90-Based Heterocomplex -- 1.4 MR Trafficking -- 1.5 Agonist Structure-Activity Relationship -- 1.6 MR Antagonism -- 1.7 MR Regulation by Phosphorylation and Redox Potential -- 1.8 Conclusions -- References -- Chapter 2: A Simple Method for Visual Assessment and Quantification of Altered Subcellular Localization of Nuclear Receptors -- 2.1 Introduction -- 2.2 Materials and Methods -- 2.3 Notes -- References -- Chapter 3: Multifaceted Effects of Ligand on Nuclear Receptor Mobility -- 3.1 Introduction -- 3.2 Nucleocytoplasmic Shuttling of the Nuclear Receptors -- 3.2.1 Nuclear Pore Complexes: Gatekeepers of the Nucleus -- 3.2.2 Nuclear Import Pathways -- 3.2.3 Nuclear Export Pathways -- 3.2.4 Dynamics of Movement Within the Nucleus -- 3.3 Ligand-Dependent Nuclear Accumulation of Nuclear Receptors -- 3.3.1 Glucocorticoid Receptor Nuclear Accumulation and Intranuclear Dynamics -- 3.3.1.1 GR Nuclear Accumulation -- 3.3.1.2 GR Intranuclear Dynamics -- 3.3.2 Mineralocorticoid Receptor Nuclear Accumulation and Intranuclear Dynamics -- 3.3.2.1 MR Nuclear Accumulation -- 3.3.2.2 MR

Intranuclear Dynamics -- 3.3.3 Androgen Receptor Nuclear Accumulation and Intranuclear Dynamics -- 3.3.3.1 Androgen Receptor Nuclear Accumulation -- 3.3.3.2 Androgen Receptor Intranuclear Dynamics -- 3.4 Ligand-Dependent Intranuclear Localization -- 3.5 Ligand-Independent Trafficking -- 3.5.1 Thyroid Hormone Receptor Intracellular Trafficking -- 3.5.2 Retinoic Acid Receptor Intracellular Trafficking -- 3.6 Retinoid X Receptor and Vitamin D Receptor Intracellular Trafficking: A Bin of Their Own? -- 3.7 Conclusions. References -- Chapter 4: Chemical Considerations in Discovery of Receptor Modulators -- 4.1 Introduction -- 4.2 Intermolecular Binding Forces Drive Ligand Action -- 4.3 Sterics and Hydrophobicity in Ligand Binding -- 4.4 Stereochemical Considerations -- 4.5 Molecular Dynamics as a Tool for Modulator Design -- 4.6 Case Study: A Holistic Approach to Liver X Receptor Modulator Design -- 4.7 Conclusions -- References -- Chapter 5: Structure-Based Design of Estrogen-Related Receptors Modulators -- 5.1 Introduction -- 5.2 Structure and Function -- 5.3 Medicinal Chemistry of ERR Modulators -- 5.3.1 ERR Inverse Agonists -- 5.3.2 ERRs Agonists -- References -- Chapter 6: PPAR and Ligand Design: Honing the Traditional Empirical Method with a More Holistic Overview -- 6.1 Introduction to the PPAR Protein -- 6.1.1 Overall PPAR LBD Protein Structure -- 6.1.2 Mechanism of PPAR Gene Transcription -- 6.1.3 Differences in LBD Between PPAR Subtypes -- 6.2 Catalogue of Known Ligands -- 6.2.1 PPAR Ligands -- 6.2.1.1 PPAR Full Agonists -- WY14643 or Pirinixic Acid -- GW590735/Compound 25a -- Pemafibrate -- 6.2.1.2 PPAR Antagonist -- GW6471 -- 6.2.2 PPAR Ligands -- 6.2.2.1 PPAR Full Agonists -- GW2433 -- GW2331 -- LC1765 -- Compound 48 -- Isoquinoline Compound 5 -- TIPP-204 -- GW0742 -- GW501516, Compounds 1-16 -- Compound 18 and Compound 13 -- 6.2.2.2 PPAR Partial Agonists -- Compound 2 -- GW9371 -- 6.2.3 Dual or Pan Agonist Ligands -- 6.2.3.1 PPAR/ Dual Agonists -- GW409544 -- Azetidinone Compounds 17 and 35 -- GL479 -- 6.2.3.2 PPAR/ Dual Agonists -- TIPP-401 -- 6.2.3.3 PPAR/ Dual Agonists -- Phenoxyacetic Acid Compounds 10 and 21 -- Sulfonylthiadiazole Compounds 6, 11t and 20a -- 6.2.3.4 Pan Agonists -- Indeglitazar -- TIPP-703 -- AL29-26 -- 6.2.3.5 Endogenous Agonists -- Eicosapentaenoic Acid (20:5 EPA) -- Vaccenic Acid (18:1) -- Iloprost. 17(S)-oxoDHA (22:6) -- 6.3 Ligand Design Factors -- 6.4 Tools and New Information -- 6.4.1 Examples of Computer-Aided Drug Design -- 6.4.2 Pharmacokinetics and Pharmacodynamics -- 6.4.3 Wider Considerations for PPAR -- 6.4.3.1 LBD Mutations -- 6.4.3.2 PPAR Intact Structure and Implications -- 6.4.3.3 Coregulators and FABPs -- 6.5 Conclusion -- References -- Chapter 7: Pregnane X Receptor: Understanding Its Function and Activity at the Molecular Level -- 7.1 Introduction -- 7.2 The Chemical Landscape of PXR Ligands -- 7.3 The Structural Architecture of PXR -- 7.4 Dimerization of PXR -- 7.5 Coregulatory Recruitment to PXR -- 7.6 AF-2 Helix Orientation Dictates PXR's Activation -- 7.7 Ligand Binding Stabilizes the Structure of PXR -- 7.8 Ligand-Binding Site of PXR and Ligand Promiscuity -- 7.9 Species Selectivity in PXR Activation -- 7.10 PXR Inhibitors -- 7.11 PXR Agonists as Therapeutics -- 7.12 Conclusion -- References -- Chapter 8: Strategies for the Design of Vitamin D Receptor Ligands -- 8.1 Introduction -- 8.2 Secosteroid VDR Ligands -- 8.3 Non-secosteroid VDR Ligands -- 8.4 VDR Antagonists -- 8.5 Concluding Remarks and Future Directions -- References -- Chapter 9: What Makes a Good Antagonist: Lessons Learned from the Estrogen and Aryl Hydrocarbon Receptors -- 9.1 Introduction: What Is an Antagonist? -- 9.2 Identification and Development of ER Antagonists -- 9.2.1 A Brief

Agonists: Potential Therapeutic Strategies for Multiple Inflammatory Diseases? -- 14.1 Introduction -- 14.2 Functions of RORs in Immune Cells -- 14.3 RORs and Autoimmune Disease -- 14.4 Vitamin D3, VDR, and RORs -- 14.5 Multiple Sclerosis (MS) -- 14.6 Psoriasis -- 14.7 Role of ROR in Cardiac Injury and Heart Failure -- 14.8 RORs in Asthma and Acute Respiratory Distress Syndrome (ARDS) -- 14.9 Rheumatoid Arthritis.
14.10 Sjögren's Syndrome (SS).